• English
  • Eesti

    PDCO meeting

    Printer-friendly version

    A core task of PDCO is to ensure that effective and safe medicines for children are available in a timely fashion. The PDCO assesses paediatric investigation plans (PIP) and adopts opinions on them, prior to an application for marketing authorization in central as well as national procedures. Assessment of full or partial waivers and applicability for deferrals are part of the PIP procedure. The PDCO consists of members and alternates chosen from the CHMP (Committee for Medicinal Products for Human use) and National Competent Authorities. The European Commission appoints three members and three alternates to represent healthcare professionals and patient organizations. The members and alternates serve on the Committee for a renewable three-year period.

    Read more about PDCO activities at the EMA website.

    During the Estonian presidency of the EU Council, a Strategic Review and Learning Meeting will be held in Tallinn on 4-6 October 2017.